7 completed. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 3 | Completed 3 |
Follow AZD 0837: new trials by email Literature Review of AZD 0837 trials Research Report on AZD 0837
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AZD0837 Extended Release (ER) Japan Study AZD0837, Placebo - Healthy | Phase 1 | Completed | AstraZeneca | 36 | 2009-05-01 | 2009-07-13 |
| Pharmacokinetics of Extended-Release Test- and Reference Formulations of AZD0837 AZD0837 - Healthy | Phase 1 | Completed | AstraZeneca | 36 | 2009-04-01 | 2009-06-03 |
| Excretion of Radiolabelled AZD0837 AZD0837 - Healthy | Phase 1 | Completed | AstraZeneca | 8 | 2009-01-01 | 2009-03-11 |
| Effect of Ketoconazole on Biliary Excretion of AZD0837 AZD0837, Ketoconazole, ketoconazole - Healthy | Phase 1 | Completed | AstraZeneca | 20 | 2008-12-01 | 2010-12-03 |
| Long-term Safety in Atrial Fibrillation Patients AZD0837, VKA INR 2-3 - Persistent or Permanent Nonvalvular Atrial Fibrillation | Phase 2 | Completed | AstraZeneca | 523 | 2007-10-01 | 2012-03-23 |
| Atrial Fibrillation (AF) Patients Not Taking Vitamin-K Antagonist (VKA) AZD0837, Aspirin - Persistent or Permanent Non-valvular Atrial Fibrillation | Phase 2 | Completed | AstraZeneca | 128 | 2007-10-01 | 2012-03-23 |
| Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation AZD0837, Vitamin-K antagonist at INR 2-3 - Nonvalvular Atrial Fibrillation | Phase 2 | Completed | AstraZeneca | 1084 | 2007-02-01 | 2012-03-23 |
AstraZeneca (7)
Sweden (4) · Denmark (1) · Japan (1) · Norway (1) · Poland (1) · Russia (1) · United Kingdom (1)
Lars Knutson, MD, PhD (2) · Gregory Y Lip, MD (1) · Gregory Y Lip, Prof (1) · Hiroyuki Fukase, MD, PhD (1) · Lars Hvilstedt Rasmussen, MD, PhD, FESC (1)